| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Skye Bioscience, Inc. | Director, 10%+ Owner | Common Stock | 8,167,206 | $28,258,532 | $3.46 | 21 Aug 2025 | By 5AM Ventures VII, L.P. |
| Enliven Therapeutics, Inc. | Director, 10%+ Owner | Common Stock | 960,383 | $14,535,397 | $15.14 | 23 Feb 2023 | Indirect |
| Camp4 Therapeutics Corp | Director, 10%+ Owner | Common Stock | 2,625,145 | $5,302,792 | $2.02 | 11 Sep 2025 | By 5AM Ventures VI, L.P. |
| Skye Bioscience, Inc. | Director, 10%+ Owner | Common Stock | 1,457,064 | $4,983,158 | $3.42 | 22 Aug 2025 | By 5AM Ventures II, L.P. |
| Camp4 Therapeutics Corp | Director, 10%+ Owner | Common Stock | 2,941,176 | $4,499,999 | $1.53 | 11 Sep 2025 | By 5AM Ventures VII, L.P. |
| Camp4 Therapeutics Corp | Director, 10%+ Owner | Common Stock | 302,770 | $611,595 | $2.02 | 11 Sep 2025 | By 5AM Opportunities II, L.P. |
| Skye Bioscience, Inc. | Director, 10%+ Owner | Common Stock | 57,493 | $196,626 | $3.42 | 22 Aug 2025 | By 5AM Co-Investors II, L.P. |
| Skye Bioscience, Inc. | Director, 10%+ Owner | Stock Option (Right to Buy) | 35,000 | $1,190 | $0.0170 | 24 Feb 2025 | Direct |
| Pear Therapeutics, Inc. | Director, 10%+ Owner | Class A Common Stock | 14,648,641 | 03 Dec 2021 | by 5AM Ventures IV, L.P. | ||
| Pear Therapeutics, Inc. | Director, 10%+ Owner | Class A Common Stock | 3,372,769 | 03 Dec 2021 | by 5AM Opportunities I, L.P. | ||
| Pear Therapeutics, Inc. | Director, 10%+ Owner | Class A Common Stock | 610,361 | 03 Dec 2021 | by 5AM Co-Investors IV, L.P. | ||
| Enliven Therapeutics, Inc. | Director, 10%+ Owner | Stock Option (right to buy) | 27,567 | 23 Feb 2023 | Direct | ||
| Camp4 Therapeutics Corp | Director, 10%+ Owner | Stock Option (Right to Buy) | 9,000 | 25 Jun 2025 | Direct | ||
| Camp4 Therapeutics Corp | Director, 10%+ Owner | Series A Prime Preferred Stock | 0 | 15 Oct 2024 | Indirect | ||
| Camp4 Therapeutics Corp | Director, 10%+ Owner | Series B Preferred Stock | 0 | 15 Oct 2024 | Indirect |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| CAMP | Camp4 Therapeutics Corp | 11 Sep 2025 | 1 | +$4,499,999 | 4 | Director, 10%+ Owner | 15 Sep 2025, 20:14 |
| SKYE | Skye Bioscience, Inc. | 21 Aug 2025 | 4 | -$800,548 | 4 | Director, 10%+ Owner | 22 Aug 2025, 19:07 |
| CAMP | Camp4 Therapeutics Corp | 25 Jun 2025 | 1 | $0 | 4 | Director, 10%+ Owner | 27 Jun 2025, 16:02 |
| SKYE | Skye Bioscience, Inc. | 24 Feb 2025 | 1 | $0 | 4 | Director | 26 Feb 2025, 19:45 |
| SKYE | Skye Bioscience, Inc. | 28 Oct 2024 | 1 | $0 | 4 | Director | 30 Oct 2024, 20:30 |
| CAMP | Camp4 Therapeutics Corp | 15 Oct 2024 | 7 | +$9,999,990 | 4 | Director, 10%+ Owner | 15 Oct 2024, 17:48 |
| CAMP | Camp4 Therapeutics Corp | 10 Oct 2024 | 0 | $0 | 3 | Director, 10%+ Owner | 10 Oct 2024, 21:05 |
| SKYE | Skye Bioscience, Inc. | 11 Sep 2024 | 6 | -$1,750,352 | 4 | Director, 10%+ Owner | 13 Sep 2024, 18:56 |
| SKYE | Skye Bioscience, Inc. | 13 Mar 2024 | 1 | +$4,500,000 | 4 | Director, 10%+ Owner | 15 Mar 2024, 16:15 |
| SKYE | Skye Bioscience, Inc. | 29 Feb 2024 | 1 | $0 | 4 | Director | 04 Mar 2024, 16:04 |
| SKYE | Skye Bioscience, Inc. | 31 Jan 2024 | 1 | +$12,026,031 | 4 | Director, 10%+ Owner | 02 Feb 2024, 16:35 |
| SKYE | Skye Bioscience, Inc. | 06 Nov 2023 | 1 | $0 | 4 | Director | 06 Nov 2023, 20:29 |
| SKYE | Skye Bioscience, Inc. | 25 Aug 2023 | 1 | $0 | 4 | Director | 29 Aug 2023, 22:36 |
| SKYE | Skye Bioscience, Inc. | 18 Aug 2023 | 6 | +$8,782,771 | 4 | Director, 10%+ Owner | 22 Aug 2023, 18:21 |
| SKYE | Skye Bioscience, Inc. | 18 Aug 2023 | 0 | $0 | 3 | Director, 10%+ Owner | 22 Aug 2023, 18:19 |
| ELVN | Enliven Therapeutics, Inc. | 23 Feb 2023 | 1 | $0 | 4 | Director, 10%+ Owner | 06 Apr 2023, 20:22 |
| ELVN | Enliven Therapeutics, Inc. | 23 Feb 2023 | 2 | $0 | 4 | Director | 27 Feb 2023, 20:55 |
| ELVN | Enliven Therapeutics, Inc. | 23 Feb 2023 | 0 | $0 | 3 | Director | 27 Feb 2023, 20:49 |
| /report/000106299321012396-schwab-andrew-j-2021-12-03 | Pear Therapeutics, Inc. | 03 Dec 2021 | 4 | +$2,000,000 | 4 | Director, 10%+ Owner | 07 Dec 2021, 16:25 |
| /report/000106299321012363-schwab-andrew-j-2021-12-03 | Pear Therapeutics, Inc. | 03 Dec 2021 | 0 | $0 | 3 | Director, 10%+ Owner | 07 Dec 2021, 16:08 |